S1PR1/S1PR4 Modulator Dosing for Safe Lymphocyte Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a safe and effective dosage and administration cycle of a modulator targeting S1PR1 and S1PR4 to treat lymphocyte-mediated diseases in humans, as existing treatments like NXC736 lack clear dosage guidelines for human applications.
Innovation Solution
A pharmaceutical composition containing a compound represented by Chemical Formula 1 or its pharmaceutically acceptable salts is administered orally at doses between 40 to 80 mg, twice daily for at least 14 days, to effectively suppress lymphocyte counts in humans, formulated as capsules or tablets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a modulator targeting S1PR1 and S1PR4 is administered to treat lymphocyte-mediated diseases, then therapeutic efficacy is improved, but the lack of clear dosage guidelines results in uncertain safety and effectiveness in human applications
Solution Approach 1:
The patent establishes specific dosage parameters (40-80 mg per day) and administration frequency parameters (once or twice daily) for the S1PR1/S1PR4 modulator, transforming the uncertain dosage regimen into defined quantitative parameters that can be reliably implemented in clinical practice
2Productivity
If the modulator is administered at higher doses to suppress lymphocyte counts more effectively, then disease treatment efficacy is improved, but the risk of adverse effects may increase
Solution Approach 1:
The patent employs a moderate dosage range (40-80 mg per day) that achieves sufficient lymphocyte suppression for therapeutic effect without excessive dosing that would increase adverse effect risk, balancing efficacy and safety through controlled partial action rather than maximum dosing
3Duration of action of stationary object
If the administration cycle is extended to maintain therapeutic effect, then disease control is improved, but the cumulative exposure and potential side effects may increase
Solution Approach 1:
The patent establishes periodic administration cycles (once or twice daily) that maintain therapeutic drug levels and disease control while allowing for metabolic clearance intervals, preventing excessive cumulative exposure through structured periodic dosing rather than continuous high-level exposure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method safely reduces absolute lymphocyte counts by 50% or more, effectively treating diseases such as alopecia areata, inflammatory bowel disease, interstitial fibrosis, and focal segmental glomerulosclerosis.
Implementation Method 1
NXC736 has a mechanism of action that binds to the Sphingosine-1 Phosphate (S1P) receptor, thereby inducing a functional antagonist effect at the receptor
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a method for administering a modulator targeting S1PR1 and S1PR4. The present invention can be effectively used in the treatment of various diseases correlated with the absolute lymphocyte count, such as alopecia, inflammatory bowel disease, interstitial fibrosis, coronary atrophy, and focal segmental glomerulosclerosis, by providing the optimal dosage and frequency of administration of a modulator (NXC736) targeting S1PR1 and S1PR4, which is capable of exhibiting excellent safety when administered to the human body and inhibiting the absolute lymphocyte count by 50% or more.